Patents by Inventor Shinobu Kuwae

Shinobu Kuwae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11624049
    Abstract: Provided is a cell suspension culturing apparatus suitable for large-scale culture of cells, the cell culturing apparatus comprising a culture solution aspirator having a double-tube structure comprising an outer tube and an inner tube inserted in a lumen of the outer tube, and a suspension culture vessel, wherein in the culture solution aspirator, the outer tube comprises a filter through which a culture solution is passed, the inner tube comprises a suction port for the culture solution passed through the filter, and an air hole which communicates the lumen of the outer tube with the outside is disposed distally in a direction of insertion of the outer tube into the suspension culture vessel.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 11, 2023
    Assignee: Orizuru Therapeutics, Inc.
    Inventors: Junji Yamaura, Shinobu Kuwae, Taro Toyoda, Shuhei Konagaya
  • Publication number: 20210381006
    Abstract: The present invention provides a method for activating/proliferating T cells, including a step of contacting a cell population containing T cells with a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface, and a method for delivering a nucleic acid into T cells, the methods including a step of contacting a cell population containing T cells simultaneously with (a) a nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface and containing a nucleic acid inside, or (b) at least one kind of T cell activating ligand, and a nucleic acid delivery carrier containing a nucleic acid inside and free of a T cell activating ligand added to its surface, a method for producing a medicament containing T cells and the like.
    Type: Application
    Filed: October 17, 2019
    Publication date: December 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu KUWAE, Satoru MATSUMOTO, Akira HAYASHI, Yoshiaki KASSAI, Kazuhide NAKAYAMA
  • Publication number: 20210052646
    Abstract: The present invention provides a lipid nanoparticle containing the following (a) to (c): (a) a nucleic acid encoding a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR); (b) a cationic lipid; and (c) a non-cationic lipid. The present invention also provides a CAR- or exogenous TCR-zo expressing immunocyte obtained by introducing the lipid nanoparticle into in vivo or ex vivo T cells, and an in vivo or ex vivo therapeutic approach using the immunocytes for disease such as cancer and the like.
    Type: Application
    Filed: December 26, 2018
    Publication date: February 25, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu KUWAE, Satoru MATSUMOTO
  • Publication number: 20200392445
    Abstract: Provided is a cell suspension culturing apparatus suitable for large-scale culture of cells, the cell culturing apparatus comprising a culture solution aspirator having a double-tube structure comprising an outer tube and an inner tube inserted in a lumen of the outer tube, and a suspension culture vessel, wherein in the culture solution aspirator, the outer tube comprises a filter through which a culture solution is passed, the inner tube comprises a suction port for the culture solution passed through the filter, and an air hole which communicates the lumen of the outer tube with the outside is disposed distally in a direction of insertion of the outer tube into the suspension culture vessel.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 17, 2020
    Applicants: Kyoto University, Takeda Phamaceutical Company Limited
    Inventors: Junji YAMAURA, Shinobu KUWAE, Taro TOYODA, Shuhei KONAGAYA
  • Patent number: 7872111
    Abstract: A protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced, are described.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 18, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Patent number: 7488591
    Abstract: A gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia is described. Also described is a means of suppressing a functional product encoded by the gene.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: February 10, 2009
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Publication number: 20090004725
    Abstract: The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
    Type: Application
    Filed: August 1, 2008
    Publication date: January 1, 2009
    Applicant: MITSUBISHI PHARMA CORPORATION
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Publication number: 20070202569
    Abstract: The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
    Type: Application
    Filed: February 16, 2007
    Publication date: August 30, 2007
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Patent number: 7198921
    Abstract: The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene encoding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genus Pichia having been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: April 3, 2007
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Publication number: 20040014170
    Abstract: The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus Pichia and provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus Pichia.
    Type: Application
    Filed: December 9, 2002
    Publication date: January 22, 2004
    Inventors: Masami Miura, Masaaki Hirose, Taeko Miwa, Hiroyuki Irie, Shinobu Kuwae, Kenmi Miyano, Wataru Otani, Hideyuki Ohi
  • Patent number: 6309864
    Abstract: A production method of a heterologous protein, comprising culturing a heterologous protein-producing host prepared by gene manipulation in a medium containing a fatty acid or a salt thereof, and a surfactant and harvesting the heterologous protein from the culture. The production amount of the heterologous protein produced by a heterologous protein-producing host can be increased. Moreover, since decomposition of the heterologous protein by an enzyme derived from the host can be inhibited, enabling large scale production of a heterologous protein.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: October 30, 2001
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Toyoo Ohda, Tomoshi Ohya, Shinobu Kuwae, Masao Ohyama, Kaoru Kobayashi, Yahiro Uemura
  • Patent number: 6068995
    Abstract: A method for producing a desired protein, which comprises growing, by a fed-batch culture, a host cell capable of expressing the desired protein, wherein the specific growth rate of the host cell is changed from the initial rate to a predetermined one by successively changing the rate of addition of a substrate which controls the growth of the host cell. According to the mode of change of the rate of substrate addition to the medium of the present invention, optimal patterns of specific growth rate .mu. and specific production rate .rho. can be realized to optimize the fed-batch culture system. As a consequence of the realization, it is made possible to perform a high density culture of the host cell by fed-batch culture, an the desired protein can be produced efficiently in a short time.
    Type: Grant
    Filed: September 19, 1996
    Date of Patent: May 30, 2000
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Kaoru Kobayashi, Kenji Tomomitsu, Shinobu Kuwae, Tomoshi Ohya, Toyoo Ohda, Takao Ohmura
  • Patent number: 5759819
    Abstract: A process for producing recombinant human serum albumin (HSA) which comprises culturing an HSA producing host prepared by gene manipulation techniques at a temperature of from 21.degree. to 29.degree. C. Culturing the HSA producing host under such a specified temperature condition makes it possible to increase productivity of HSA production, improve the growth yield of an HSA producing host, and reduce the degree of coloring in the HSA preparation.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: June 2, 1998
    Assignee: The Green Cross Corporation
    Inventors: Kaoru Kobayashi, Kenji Tomomitsu, Shinobu Kuwae, Tomoshi Ohya, Toyoo Ohda
  • Patent number: 5691451
    Abstract: A recombinant human serum albumin (rHSA) pharmaceutical preparation is sterilized by subjecting a pharmaceutical preparation of rHSA obtained by gene manipulation techniques packed in a container in an administration unit to heat treatment at 50.degree. to 80.degree. C. for 30 minutes or more. By the disclosed method, rHSA having high safety can be provided since microorganisms contaminated in rHSA pharmaceutical preparations die as a result of the sterilization method of the present invention.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: November 25, 1997
    Assignee: The Green Cross Corporation
    Inventors: Tomoshi Ohya, Toyoo Ohda, Shinobu Kuwae, Kenji Tomomitsu, Kaoru Kobayashi, Takao Ohmura
  • Patent number: 5631145
    Abstract: A process for producing recombinant human serum albumin (HSA) which comprises culturing an HSA producing host prepared by gene manipulation techniques at a temperature of from 21.degree. to 29.degree. C. Culturing the HSA producing host under such a specified temperature condition makes it possible to increase productivity of HSA production, improve the growth yield of an HSA producing host, and reduce the degree of coloring in the HSA preparation.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: May 20, 1997
    Assignee: The Green Cross Corporation
    Inventors: Kaoru Kobayashi, Kenji Tomomitsu, Shinobu Kuwae, Tomoshi Ohya, Toyoo Ohda
  • Patent number: 5612197
    Abstract: A process for producing recombinant human serum albumin is disclosed, which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques in a medium that contains an amino acid, preferably at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, tryptophan, valine, isoleucine, phenylalanine, cysteine and arginine, more preferably histidine. The process can significantly increase the yield of human serum albumin over that produced by known processes.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: March 18, 1997
    Assignee: The Green Cross Corporation
    Inventors: Toyoo Ohda, Wataru Ohtani, Tomoshi Ohya, Shinobu Kuwae, Kenji Tomomitsu, Kaoru Kobayashi, Takao Ohmura
  • Patent number: 5334512
    Abstract: A method for producing human serum albumin which comprises cultivating a human serum albumin-producing host prepared by genetic engineering, in a medium containing a fatty acid having 10 to 26 carbon atoms, or its salt, and a method for cultivating the host. HSA production can be greatly increased by the present invention.
    Type: Grant
    Filed: March 20, 1992
    Date of Patent: August 2, 1994
    Assignee: The Green Cross Corporation
    Inventors: Kaoru Kobayashi, Shinobu Kuwae, Tomoshi Ooya, Hirotoshi Fukutsuka, Akinori Sumi, Wataru Ohtani, Takao Ohmura, Kazumasa Yokoyama
  • Patent number: 5294699
    Abstract: A method of inhibiting the coloration of human serum albumin expressed by using the gene manipulation technology which method comprises separating coloring contaminants from said human serum albumin before said coloring contaminants bind to the human serum albumin.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: March 15, 1994
    Assignee: The Green Cross Corporation
    Inventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Fuluhata, Kaoru Kobayashi, Shinobu Kuwae, Hirotoshi Fukutsuka, Tomoshi Ohya, Hiroshi Morise